Skip to Primary Content
Skip to Footer
home
about
products & pipeline
Clinical Trials
Publications
newsroom
investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
ESG
Financial Information
partners
careers
Afrezza.com
818.661.5000
careers
partners
investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
ESG
Financial Information
newsroom
products & pipeline
Clinical Trials
Publications
about
News & Events
January 9, 2022
Clofazimine Inhalation Suspension
(MNKD-101)
nontuberculous mycobacterial lung disease
previous post
next post
×
